Top

Neurological Sciences

Published in:

09-11-2023 | Myasthenia Gravis | Original Article

Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study

Authors: Wei Zheng, Xiaoxia Cao, Jing Luo, Zhuoting Liu, Wenjun Que, Xia Guo, Rui Fan, Quanxin Long, Fei Xiao

Published in: Neurological Sciences | Issue 4/2024

Abstract

Background and objectives

Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction. No cohort study has investigated the efficacy of inactivated vaccines in patients with MG.

Materials and methods

This prospective observational cohort study included healthy controls (HCs) and patients with MG with or without immunosuppressive treatment. Vaccination occurred between May and December 2021. Patients with MG were subjected to a clinical scale assessment for disease severity. The neutralization antibodies (Nabs) levels were measured in all participants using the pseudovirus neutralization assay.

Results

Twenty-one patients (Female/Male:10/11); age median [interquartile range (IQR)]: 43 [30, 56]) were included in this study. Two patients (2/21) were lost during follow-up after enrollment. No sustained vaccine-related adverse effects occurred in any visit of patients with MG. No exacerbation of MG was observed. Acetylcholine receptor antibody (AChR-Ab) levels showed no statistically significant changes between the first and second visit (median [IQR]: 2.22 [0.99, 2.63] nmol/L vs. 1.54 [1.07, 2.40] nmol/L, p = 0.424). However, levels of AChR-Ab decreased at the third visit (median [IQR]: 2.22 [0.96, 2.70] nmol/L vs. 1.69 [0.70, 1.85] nmol/L, p = 0.011). No statistically significant difference in Nabs levels was found between HCs and patients with MG (median [IQR]: 102.89 [33.13, 293.86] vs. 79.29 [37.50, 141.93], p = 0.147).

Discussion

The safety of the SARS-CoV-2 inactivated vaccine was reconfirmed in this study. No significant difference in Nabs level was found between patients with MG and HCs. Nabs levels correlated with AChR-Ab levels before vaccination and ΔAChR-Ab levels.

Available only for authorised users

Muppidi S, Guptill JT, Jacob S et al (2020) COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol 19:970–971. https://doi.org/10.1016/S1474-4422(20)30413-0CrossRefPubMedPubMedCentral

Jakubíková M, Týblová M, Tesař A et al (2021) Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol 28:3418–3425. https://doi.org/10.1111/ene.14951CrossRefPubMedPubMedCentral

Solé G, Mathis S, Friedman D et al (2021) Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis. Neurology 96:e2109–e2120. https://doi.org/10.1212/WNL.0000000000011669CrossRefPubMed

Jara A, Undurraga EA, González C et al (2021) Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med 385:875–884. https://doi.org/10.1056/NEJMoa2107715CrossRefPubMed

Ruan Z, Tang Y, Li C et al (2021) COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series. Vaccines (Basel) 9:1112. https://doi.org/10.3390/vaccines9101112CrossRefPubMed

Zhou Q, Zhou R, Yang H, Yang H (2021) To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis. Front Immunol 12:733418. https://doi.org/10.3389/fimmu.2021.733418CrossRefPubMedPubMedCentral

Lotan I, Hellmann MA, Friedman Y et al (2022) Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis. Neuromuscul Disord 32:230–235. https://doi.org/10.1016/j.nmd.2022.01.013CrossRefPubMedPubMedCentral

Lupica A, Di Stefano V, Iacono S et al (2022) Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort. Neurol Int 14:406–416. https://doi.org/10.3390/neurolint14020033CrossRefPubMedPubMedCentral

Sansone G, Bonifati DM (2022) Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients. J Neurol 269(8):3965–3981. https://doi.org/10.1007/s00415-022-11140-9CrossRefPubMedPubMedCentral

10.

Li H-Y, Shao L-Y, Song M et al (2022) Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study. Front Immunol 13:923017. https://doi.org/10.3389/fimmu.2022.923017CrossRefPubMedPubMedCentral

11.

Farina A, Falso S, Cornacchini S et al (2022) Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience. Eur J Neurol 29(8):2505–2510. https://doi.org/10.1111/ene.15348CrossRefPubMedPubMedCentral

12.

Gamez J, Gamez A, Carmona F (2022) Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis. Muscle Nerve 66:612–617. https://doi.org/10.1002/mus.27703CrossRefPubMed

13.

Urra Pincheira A, Alnajjar S, Katzberg H et al (2022) Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis. Muscle Nerve 66:558–561. https://doi.org/10.1002/mus.27657CrossRefPubMed

14.

Doron A, Piura Y, Vigiser I et al (2022) BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves. J Neurol 269:6193–6201. https://doi.org/10.1007/s00415-022-11303-8CrossRefPubMedPubMedCentral

15.

Wang HY, Qiu L, Ou CY et al (2023) An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis. Neurol Sci 1–7. https://doi.org/10.1007/s10072-023-06811-y

16.

Ruan Z, Huan X, Su Y et al (2023) Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study. Front Immunol 14:1141983. https://doi.org/10.3389/fimmu.2023.1141983CrossRefPubMedPubMedCentral

17.

Yao H, Song Y, Chen Y et al (2020) Molecular Architecture of the SARS-CoV-2 Virus. Cell 183:730-738.e13. https://doi.org/10.1016/j.cell.2020.09.018CrossRefPubMedPubMedCentral

18.

Ren L-L, Wang Y-M, Wu Z-Q et al (2020) Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 133:1015–1024. https://doi.org/10.1097/CM9.0000000000000722CrossRefPubMed

19.

Kim D, Lee J-Y, Yang J-S et al (2020) The Architecture of SARS-CoV-2 Transcriptome. Cell 181:914-921.e10. https://doi.org/10.1016/j.cell.2020.04.011CrossRefPubMedPubMedCentral

20.

Shang J, Wan Y, Luo C et al (2020) Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117:11727–11734. https://doi.org/10.1073/pnas.2003138117ADSCrossRefPubMedPubMedCentral

21.

McCallum M, Walls AC, Bowen JE et al (2020) Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nat Struct Mol Biol 27:942–949. https://doi.org/10.1038/s41594-020-0483-8CrossRefPubMedPubMedCentral

22.

Hu J, Gao Q, He C et al (2020) Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis 7:551–557. https://doi.org/10.1016/j.gendis.2020.07.006CrossRefPubMedPubMedCentral

23.

Nie J, Li Q, Wu J et al (2020) Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc 15:3699–3715. https://doi.org/10.1038/s41596-020-0394-5CrossRefPubMed

24.

Hyseni I, Molesti E, Benincasa L et al (2020) Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses 12:E1011. https://doi.org/10.3390/v12091011CrossRef

25.

Li Q, Liu Q, Huang W et al (2018) Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol 28:e1963. https://doi.org/10.1002/rmv.1963CrossRefPubMed

26.

Zhang L, Li Q, Liu Q et al (2017) A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system. Hum Vaccin Immunother 13:1811–1817. https://doi.org/10.1080/21645515.2017.1325050CrossRefPubMedPubMedCentral

27.

Wang B, Wang B, Liu P et al (2014) Package of NDV-pseudotyped HIV-Luc virus and its application in the neutralization assay for NDV infection. PLoS ONE 9:e99905. https://doi.org/10.1371/journal.pone.0099905ADSCrossRefPubMedPubMedCentral

28.

Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23. https://doi.org/10.1212/wnl.55.1.16CrossRefPubMed

29.

Raja SM, Howard JF, Juel VC et al (2019) Clinical outcome measures following plasma exchange for MG exacerbation. Ann Clin Transl Neurol 6:2114–2119. https://doi.org/10.1002/acn3.50901CrossRefPubMedPubMedCentral

30.

Tackenberg B, Schneider M, Blaes F et al (2018) Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial). EBioMedicine 28:143–150. https://doi.org/10.1016/j.ebiom.2018.01.007CrossRefPubMedPubMedCentral

31.

Toplak N, Kveder T, Trampus-Bakija A et al (2008) Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev 8:134–138. https://doi.org/10.1016/j.autrev.2008.07.008CrossRefPubMed

32.

Lazaridis K, Tzartos SJ (2020) Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol 11:212. https://doi.org/10.3389/fimmu.2020.00212CrossRefPubMedPubMedCentral

33.

Shao K, Yue Y-X, Zhao L-M et al (2022) Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients. Clin Chim Acta 533:122–130. https://doi.org/10.1016/j.cca.2022.06.017CrossRefPubMed

34.

Gummi RR, Kukulka NA, Deroche CB, Govindarajan R (2019) Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 60:693–699. https://doi.org/10.1002/mus.26689CrossRefPubMed

35.

Alcantara M, Koh M, Park AL et al (2023) Outcomes of COVID-19 Infection and Vaccination Among Individuals With Myasthenia Gravis. JAMA Netw Open 6:e239834. https://doi.org/10.1001/jamanetworkopen.2023.9834CrossRefPubMedPubMedCentral

36.

Di Stefano V, Lupica A, Rispoli MG et al (2020) Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry 91:392–395. https://doi.org/10.1136/jnnp-2019-322606CrossRefPubMed

37.

Medeiros-Ribeiro AC, Aikawa NE, Saad CGS et al (2021) Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med 27:1744–1751. https://doi.org/10.1038/s41591-021-01469-5CrossRefPubMed

38.

Aikawa NE, Kupa LVK, Pasoto SG et al (2022) Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatol 4:e113–e124. https://doi.org/10.1016/S2665-9913(21)00327-1CrossRefPubMed

39.

Plymate LC, Pepper G, Krist MP, Koelle DM (2021) Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab. J Transl Autoimmun 4:100114. https://doi.org/10.1016/j.jtauto.2021.100114CrossRefPubMedPubMedCentral

40.

Golding B, Lee Y, Golding H, Khurana S (2021) Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report. Ann Rheum Dis 80:1359–1361. https://doi.org/10.1136/annrheumdis-2021-220993CrossRefPubMed

41.

Krammer F (2020) SARS-CoV-2 vaccines in development. Nature 586:516–527. https://doi.org/10.1038/s41586-020-2798-3ADSCrossRefPubMed

42.

Sommer N, Tackenberg B, Hohlfeld R (2008) The immunopathogenesis of myasthenia gravis. Handb Clin Neurol 91:169–212. https://doi.org/10.1016/S0072-9752(07)01505-9CrossRefPubMed

43.

Vista ES, Crowe SR, Thompson LF et al (2012) Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus. Lupus 21:168–174. https://doi.org/10.1177/0961203311429554CrossRefPubMedPubMedCentral

44.

Cai Y, Han L, Zhu D et al (2021) A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis. Front Immunol 12:666046. https://doi.org/10.3389/fimmu.2021.666046CrossRefPubMedPubMedCentral

45.

Gambino CM, Agnello L, Lo Sasso B et al (2021) Comparative Analysis of BIOCHIP Mosaic-Based Indirect Immunofluorescence with Enzyme-Linked Immunosorbent Assay for Diagnosing Myasthenia Gravis. Diagnostics (Basel) 11:2098. https://doi.org/10.3390/diagnostics11112098CrossRefPubMed

46.

Yu X, Qi X, Cao Y et al (2022) Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant. Emerg Microbes Infect 11:749–752. https://doi.org/10.1080/22221751.2022.2044271CrossRefPubMedPubMedCentral

Title: Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study
Authors: Wei Zheng
Xiaoxia Cao
Jing Luo
Zhuoting Liu
Wenjun Que
Xia Guo
Rui Fan
Quanxin Long
Fei Xiao
Publication date: 09-11-2023
Publisher: Springer International Publishing
Keywords: Myasthenia Gravis
SARS-CoV-2
Vaccination
Published in: Neurological Sciences / Issue 4/2024
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07186-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study

Abstract

Background and objectives

Materials and methods

Results

Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and objectives

Materials and methods

Results

Discussion

Please log in to get access to this content

Other articles of this Issue 4/2024

The diagnostic assessment of fibromyalgia and the role of small fiber pathology

Prevalence, characteristics, and risk factors of venous thromboembolism in patients with brain tumor undergoing craniotomy: a meta-analysis

Imbalance and gait impairment in Parkinson’s disease: discussing postural instability and ataxia

Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis

Is physiotherapy in migraines known to sufferers? A cross-sectional study

Malignant atrophic papulosis (Degos disease) with central nervous system involvement